admed laboratory adopts QuantaMatrix dRAST solution in routine clinical use
QuantaMatrix, an in vitro diagnostics company specializing in the discovery, development and commercialization of fully integrated solutions within the sepsis value chain, today announces that its dRAST™ solution has been adopted for routine clinical use by admed, a Swiss-based laboratory.
Source: biospace.com